Bruker (NASDAQ:BRKR) Downgraded by JPMorgan Chase & Co. to “Neutral”

Bruker (NASDAQ:BRKR) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, October 14th, Marketbeat Ratings reports. They currently have a $60.00 price objective on the medical research company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential downside of 3.23% from the company’s previous close.

BRKR has been the topic of several other reports. TD Cowen lifted their target price on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. The Goldman Sachs Group upgraded shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research report on Monday, September 21st. Citigroup lowered their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Barclays lifted their target price on Bruker from $58.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.43.

Bruker Trading Up 2.1%

NASDAQ:BRKR traded up $1.26 during trading hours on Wednesday, hitting $62.00. The company had a trading volume of 2,990,655 shares, compared to its average volume of 2,354,395. The company has a market capitalization of $9.45 billion, a PE ratio of -88.57, a price-to-earnings-growth ratio of 1.76 and a beta of 1.22. The stock has a 50-day moving average price of $58.79 and a 200 day moving average price of $50.25. Bruker has a 52 week low of $32.37 and a 52 week high of $66.98. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The company had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the prior year, the firm earned $0.32 earnings per share. Bruker’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts predict that Bruker will post 2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president directly owned 134,806 shares in the company, valued at $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 27.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in BRKR. Global Retirement Partners LLC acquired a new position in shares of Bruker in the 2nd quarter valued at $38,000. Root Financial Partners LLC purchased a new stake in shares of Bruker during the 3rd quarter worth about $57,000. Essential Partners LLC bought a new stake in shares of Bruker during the first quarter valued at approximately $36,000. FNY Investment Advisers LLC acquired a new position in shares of Bruker in the 2nd quarter valued at $60,000. Finally, IFP Advisors Inc grew its stake in Bruker by 88.6% in the second quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock valued at $64,000 after purchasing an additional 498 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.